ClinicalTrials.gov
public full text
Public Domain
NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- HER2-Ultralow: Prevalence, Characteristics, and Treatment Choices Among Advanced Breast Cancer Patients With Tumors Initially Scored as IHC 0.#312635
- Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer#907036
- International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-Low and Ultralow Categories#464248
- S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity#407785
- Supplemental Material For: Real-World Biomarker Testing and Treatment Patterns in HR+/HER2− Metastatic Breast Cancer: Insights from the AGO QS-Mamma Registry 2024#1090092
Record · ID 158227
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive